Journal article
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection
- Abstract:
-
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, p... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 1.1MB)
-
(Accepted manuscript, pdf, 190.9KB)
-
(Accepted manuscript, pdf, 252.0KB)
-
- Publisher copy:
- 10.1016/j.vaccine.2018.09.070
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
ReiThera SRL
More from this funder
NIHR Oxford Biomedical Research
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Vaccine Journal website
- Volume:
- 36
- Issue:
- 46
- Pages:
- 6988-6994
- Publication date:
- 2018-10-11
- Acceptance date:
- 2018-09-29
- DOI:
- EISSN:
-
1873-2518
- ISSN:
-
0264-410X
- Pmid:
-
30318168
- Source identifiers:
-
928824
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:928824
- UUID:
-
uuid:3fbfa840-27b4-4cbe-915a-bb55fc1ef02f
- Local pid:
- pubs:928824
- Deposit date:
- 2018-10-20
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.vaccine.2018.09.070
If you are the owner of this record, you can report an update to it here: Report update to this record